Department of Internal Medicine, University of Michigan, Ann Arbor.
VA Center for Clinical Management Research, Ann Arbor, Michigan.
JAMA Intern Med. 2022 Aug 1;182(8):805-813. doi: 10.1001/jamainternmed.2022.2291.
Some experts have cautioned that national and health system emphasis on rapid administration of antimicrobials for sepsis may increase overall antimicrobial use even among patients without sepsis.
To assess whether temporal changes in antimicrobial timing for sepsis are associated with increasing antimicrobial use, days of therapy, or broadness of antimicrobial coverage among all hospitalized patients at risk for sepsis.
DESIGN, SETTING, AND PARTICIPANTS: This is an observational cohort study of hospitalized patients at 152 hospitals in 2 health care systems during 2013 to 2018, admitted via the emergency department with 2 or more systemic inflammatory response syndrome (SIRS) criteria. Data analysis was performed from June 10, 2021, to March 22, 2022.
Hospital-level temporal trends in time to first antimicrobial administration.
Antimicrobial outcomes included antimicrobial use, days of therapy, and broadness of antibacterial coverage. Clinical outcomes included in-hospital mortality, 30-day mortality, length of hospitalization, and new multidrug-resistant (MDR) organism culture positivity.
Among 1 559 523 patients admitted to the hospital via the emergency department with 2 or more SIRS criteria (1 269 998 male patients [81.4%]; median [IQR] age, 67 [59-77] years), 273 255 (17.5%) met objective criteria for sepsis. In multivariable models adjusted for patient characteristics, the adjusted median (IQR) time to first antimicrobial administration to patients with sepsis decreased by 37 minutes, from 4.7 (4.1-5.3) hours in 2013 to 3.9 (3.6-4.4) hours in 2018, although the slope of decrease varied across hospitals. During the same period, antimicrobial use within 48 hours, days of antimicrobial therapy, and receipt of broad-spectrum coverage decreased among the broader cohort of patients with SIRS. In-hospital mortality, 30-day mortality, length of hospitalization, new MDR culture positivity, and new MDR blood culture positivity decreased over the study period among both patients with sepsis and those with SIRS. When examining hospital-specific trends, decreases in antimicrobial use, days of therapy, and broadness of antibacterial coverage for patients with SIRS did not differ by hospital antimicrobial timing trend for sepsis. Overall, there was no evidence that accelerating antimicrobial timing for sepsis was associated with increasing antimicrobial use or impaired antimicrobial stewardship.
In this multihospital cohort study, the time to first antimicrobial for sepsis decreased over time, but this trend was not associated with increasing antimicrobial use, days of therapy, or broadness of antimicrobial coverage among the broader population at-risk for sepsis, which suggests that shortening the time to antibiotics for sepsis is feasible without leading to indiscriminate antimicrobial use.
一些专家警告说,国家和卫生系统强调对脓毒症快速使用抗生素可能会增加总体抗生素使用量,即使在没有脓毒症的患者中也是如此。
评估脓毒症抗生素使用时间的时间变化是否与所有有脓毒症风险的住院患者的抗生素使用量增加、治疗天数或抗生素覆盖范围的广泛程度相关。
设计、地点和参与者:这是一项观察性队列研究,纳入了 2013 年至 2018 年间在 2 个医疗保健系统的 152 家医院就诊的因 2 个或更多全身炎症反应综合征(SIRS)标准通过急诊入院的所有住院患者,数据分析于 2021 年 6 月 10 日至 2022 年 3 月 22 日进行。
医院层面首次使用抗生素的时间趋势。
包括抗生素使用、治疗天数和抗菌覆盖范围广泛程度在内的抗生素结果。临床结果包括院内死亡率、30 天死亡率、住院时间和新的多药耐药(MDR)生物体培养阳性。
在这项多医院队列研究中,脓毒症的首次抗生素使用时间随着时间的推移而缩短,但这一趋势与更广泛的脓毒症风险人群的抗生素使用量增加、治疗天数或抗生素覆盖范围的广泛程度无关,这表明在不导致抗生素滥用的情况下,缩短脓毒症使用抗生素的时间是可行的。